Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Northern Trust Corp

Northern Trust Corp increased its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 28.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 318,177 shares of the company's stock after acquiring an additional 70,497 shares during the period. Northern Trust Corp owned approximately 0.85% of Entrada Therapeutics worth $5,501,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TRDA. Vanguard Group Inc. boosted its holdings in Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock worth $25,317,000 after buying an additional 241,052 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Entrada Therapeutics by 123.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock worth $3,847,000 after buying an additional 122,823 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Entrada Therapeutics by 127.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock worth $3,752,000 after purchasing an additional 121,598 shares in the last quarter. Federated Hermes Inc. lifted its stake in Entrada Therapeutics by 3,104.3% in the 4th quarter. Federated Hermes Inc. now owns 99,814 shares of the company's stock worth $1,726,000 after purchasing an additional 96,699 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Entrada Therapeutics by 77.2% in the 4th quarter. Renaissance Technologies LLC now owns 166,200 shares of the company's stock worth $2,874,000 after purchasing an additional 72,400 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Price Performance

Shares of TRDA stock traded down $0.12 during trading on Friday, hitting $7.50. 103,059 shares of the stock traded hands, compared to its average volume of 130,598. The firm has a market capitalization of $284.65 million, a P/E ratio of 4.72 and a beta of 0.04. The firm's fifty day moving average price is $8.64 and its 200-day moving average price is $13.11. Entrada Therapeutics, Inc. has a 52-week low of $7.10 and a 52-week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The firm had revenue of $8.75 million for the quarter, compared to analyst estimates of $10.98 million. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.